 This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, predictive biomarkers and pharmacokinetics pharmacodynamics of durvalumab in combination with R-CHOP Arm A or R2-CHOP Arm B, followed by durvalumab consolidation therapy in previously untreated subjects with high-risk DLBCL. 